Research programme - cancer therapeutics - Eureka Therapeutics

Drug Profile

Research programme - cancer therapeutics - Eureka Therapeutics

Alternative Names: ET 1402; ET 1402L1; ET 1501; ET 1502; ET 1504; ET 190

Latest Information Update: 20 Jan 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Eureka Therapeutics
  • Class Antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Haematological malignancies; Liver cancer
  • Research Cervical cancer; Head and neck cancer; Lung cancer; Prostate cancer

Most Recent Events

  • 03 Dec 2016 Pharmacodynamics data from a preclinical trial in Haematological malignancies presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH-2016)
  • 16 Apr 2016 Pharmacodynamics data from a preclinical study for Liver cancer (Hepatocellular carcinoma) presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
  • 16 Apr 2016 Eureka Therapeutics plans a phase I trial for Liver cancer in 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top